NEXGEL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
NEXGEL, INC. (NXGL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.42% for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2023-11-13
- NEXGEL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 0.86%, a 0.00% change year-over-year.
- NEXGEL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 0.86%.
- NEXGEL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 0.86%, a 38.13% decline from fiscal 2020.
- NEXGEL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.39%, a 0.00% change from fiscal 2019.
- NEXGEL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 1.39%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2023-09-30 | 4.42% 10-Q · filed 2023-11-13 | |||
| 2022-09-30 | 0.86% 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | 0.86% 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | 0.86% 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 0.86% 10-K · filed 2022-03-21 | |||
| 2021-09-30 | 0.86% 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 0.86% 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | 0.86% 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | 1.39% 10-K · filed 2021-03-31 | |||
| 2020-09-30 | 1.39% 10-Q · filed 2020-11-16 | |||
| 2019-12-31 | 1.39% 10-K/A · filed 2020-04-03 | |||
| 2019-09-30 | 1.39% 10-Q · filed 2020-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |